Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Novo Japan Chief Sees 100 Billion Yen Target Achievable on Ozempic, Rybelsus
Novo Nordisk sees plenty of opportunities that would help it eventually achieve Japan sales of 100 billion yen as it gears up to push its new once-weekly GLP-1 agent Ozempic (semaglutide) and a just-approved once-daily oral version Rybelsus, the company’s…
To read the full story
Related Article
- Novo Nordisk Logs 3.6% Growth in Japan in 2024, Driven by Semaglutide
April 28, 2025
- Novo Japan’s Revenue Hits Record Yet Again in 2023 with 8.5% Growth
April 25, 2024
- Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom
April 12, 2023
- Novo Japan’s Sales Hit 100 Billion Yen Mark in 2021, but President Frets Future Investments
April 21, 2022
- Novo Japan Notches 10% Growth in 2020, President Proud of This Feat amid Market Decline
April 13, 2021
- Novo to Skip August Listing for 1st Oral GLP Agent Rybelsus
August 18, 2020
- Novo Nordisk Poised to Cash in on New GLP-1 Agents to Hit 100 Billion Yen Japan Sales
October 3, 2019
- With Ozempic Listing in Limbo, Novo Japan Chief Says Single-Dose Device Launch Unlikely This Year
April 17, 2019
BUSINESS
- Eisai to Raise 50 Billion Yen via Bond Issue for R&D, Licensing
June 5, 2026
- Japan Market for Fertility, Contraception, Female Disorders Put at 228.5 Billion Yen by FY2035
June 5, 2026
- Toho, DHL Partner on Healthcare Logistics Platform
June 5, 2026
- Keytruda Maintains Lead as Japan’s Top-Selling Drug for 32nd Month: Encise
June 5, 2026
- Boehringer’s Japan Pharma Sales Up for 7th Straight Year, 10-Plus Launches Eyed by 2030
June 4, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…